Meeting
2022 ASCO Annual Meeting
Multimodal machine learning model prediction of complete pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
Authors
David Groheux
Hôpital Saint Louis, AP-HP, Paris, France
David Groheux , Loïc Ferrer , Jennifer Vargas , Antoine Martineau , Luis Teixeira , Philippe Menu , Philippe Bertheau , Olivier Gallinato , Thierry Colin , Jacqueline Lehmann-Che
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 601)
DOI
10.1200/JCO.2022.40.16_suppl.601
Abstract #
601
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
First Author: Roberto Antonio Leon-Ferre
Poster
2023 ASCO Annual Meeting
Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.
First Author: Cheng Wang
Poster
2022 ASCO Annual Meeting
Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.
First Author: Sherene Loi
Poster
2022 ASCO Annual Meeting
Does race influence long-term outcomes after neoadjuvant chemotherapy in breast cancer: A National Cancer Database analysis.
First Author: Arya Mariam Roy